UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Outcomes of patients with hereditary transthyretin-mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a Phase 3 study of patisiran

Revue neurologique, 2019-04, Vol.175, p.S129-S129

2019

Volltextzugriff (PDF)

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction

European journal of heart failure, 2017-01, Vol.19 (1), p.129-137

2017

Volltextzugriff (PDF)

Natriuretic peptides in cardiovascular diseases: current use and perspectives

European heart journal, 2014-02, Vol.35 (7), p.419-425

2014

Volltextzugriff (PDF)

Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM‐HF study

European journal of heart failure, 2024-07, Vol.26 (7), p.1507-1517

2024

Volltextzugriff (PDF)

Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF

JACC. Heart failure, 2022-02, Vol.10 (2), p.119-128

2022

Volltextzugriff (PDF)

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial

JACC. Heart failure, 2020-10, Vol.8 (10), p.811-818

2020

Volltextzugriff (PDF)

Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment

Hypertension research, 2021-10, Vol.44 (10), p.1239-1250

2021

Volltextzugriff (PDF)

Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

JACC. Heart failure, 2021-12, Vol.9 (12), p.876-886

2021

Volltextzugriff (PDF)

Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure

Cellular and molecular life sciences : CMLS, 2023-05, Vol.80 (5), p.134-134, Article 134

2023

Volltextzugriff (PDF)

Reverse Remodeling Effects of Sacubitril-Valsartan: Structural and Functional Optimization in Stage C Heart Failure

The American journal of cardiology, 2024-01, Vol.210, p.249-255

2024

Volltextzugriff (PDF)

Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update

Expert opinion on pharmacotherapy, 2022-04, Vol.23 (6), p.673-680

2022

Volltextzugriff (PDF)

Effects of angiotensin receptor-neprilysin inhibitor on ketone body metabolism in pre-heart failure/heart failure patients

Scientific reports, 2024-07, Vol.14 (1), p.16493-9, Article 16493

2024

Volltextzugriff (PDF)

Chronic Kidney Disease as a Comorbidity in Heart Failure

International journal of molecular sciences, 2023-02, Vol.24 (3), p.2988

2023

Volltextzugriff (PDF)

Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples

Clinical research in cardiology, 2024-06, Vol.113 (6), p.856-865

2024

Volltextzugriff (PDF)

Can HFpEF and HFrEF Coexist?

Circulation (New York, N.Y.), 2020-03, Vol.141 (9), p.709-711

2020

Volltextzugriff (PDF)

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients

European journal of clinical pharmacology, 2022-01, Vol.78 (1), p.19-25

2022

Volltextzugriff (PDF)

Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013–2020

Clinical research in cardiology, 2024-09, Vol.113 (9), p.1355-1368

2024

Volltextzugriff (PDF)

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease

Journal of the American Heart Association, 2022-09, Vol.11 (18), p.e026407

2022

Volltextzugriff (PDF)

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

Journal of the American College of Cardiology, 2019-08, Vol.74 (5), p.683-698

2019

Volltextzugriff (PDF)

The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review

Indian heart journal, 2024-07, Vol.76 (4), p.229-239

2024

Volltextzugriff (PDF)

Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system

Biomedicine & pharmacotherapy, 2024-04, Vol.173, p.116391-116391, Article 116391

2024

Volltextzugriff (PDF)

Combined effects of sodium-glucose cotransporter 2 inhibitor and angiotensin receptor-neprilysin inhibitor on renal function in cardiovascular disease patients with type 2 diabetes mellitus: a retrospective cohort study

Frontiers in endocrinology (Lausanne), 2024-01, Vol.14, p.1326611-1326611

2024

Volltextzugriff (PDF)

The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond

Current cardiology reports, 2018-01, Vol.20 (1), p.5-5, Article 5

Kario, Kazuomi

2018

Volltextzugriff (PDF)

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction

Clinical research in cardiology, 2023-01, Vol.112 (1), p.167-174

2023

Volltextzugriff (PDF)

Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan

Journal of cardiovascular pharmacology and therapeutics, 2020-03, Vol.25 (2), p.152-157

2020

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(50)
Bücher
(1)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

Humans
(47)
Science & Technology
(47)
Life Sciences & Biomedicine
(46)
Arni
(39)
Heart Failure - Drug Therapy
(38)
Angiotensin Receptor Antagonists - Therapeutic Use
(37)
Heart Failure
(35)
Cardiovascular System & Cardiology
(32)
Cardiac & Cardiovascular Systems
(31)
Drug Combinations
(27)
Aminobutyrates - Therapeutic Use
(23)
Tetrazoles - Therapeutic Use
(22)
Stroke Volume
(20)
Male
(18)
Aged
(17)
Heart Failure - Physiopathology
(17)
Neprilysin - Antagonists & Inhibitors
(17)
Female
(16)
Neprilysin
(16)
Ejection Fraction
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Outcomes of patients with hereditary transthyretin-mediated amyloidosis with early onset V30M versus all other mutations in APOLLO, a Phase 3 study of patisiran

Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction

Natriuretic peptides in cardiovascular diseases: current use and perspectives

Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM‐HF study

Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF

Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial

Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment

Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

Atrial natriuretic peptide stimulates autophagy/mitophagy and improves mitochondrial function in chronic heart failure

Reverse Remodeling Effects of Sacubitril-Valsartan: Structural and Functional Optimization in Stage C Heart Failure

Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update

Effects of angiotensin receptor-neprilysin inhibitor on ketone body metabolism in pre-heart failure/heart failure patients

Chronic Kidney Disease as a Comorbidity in Heart Failure

Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples

Can HFpEF and HFrEF Coexist?

Low- vs high-dose ARNI effects on clinical status, exercise performance and cardiac function in real-life HFrEF patients

Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013–2020

Sacubitril/Valsartan in Patients With Heart Failure and Concomitant End-Stage Kidney Disease

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5)

The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review

Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system

Combined effects of sodium-glucose cotransporter 2 inhibitor and angiotensin receptor-neprilysin inhibitor on renal function in cardiovascular disease patients with type 2 diabetes mellitus: a retrospective cohort study

The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction

Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan

Suchergebnisse filtern